Preventive effects of Bifidobacterium- and Lactobacillus-fermented milk on the development of inflammatory bowel disease in senescence-accelerated mouse P1/Yit strain mice.
OBJECTIVE
We recently discovered inflammatory bowel disease (IBD) in the ileum and cecum of SAMP1/Yit strain mice under specific pathogen-free (SPF) conditions. To determine the effect of lactic acid bacteria (LAB - Bifidobacterium breve, Bifidobacterium bifidum and Lactobacillus acidophilus)-fermented milk on the prevention of IBD in SAMP1/Yit strain mice, we compared the disease severity on the intestinal inflammation among the group of mice fed saline, unfermented milk or LAB-fermented milk.


METHODS
Three-week-old SAMP1/Yit strain mice (n = 72) were subdivided into three groups, that were fed saline, unfermented milk and LAB-fermented milk, respectively. The diets were orally administered daily via a gastric tube. When the mice reached 20 weeks of age, they were sacrificed and the IBD scores were compared among the three groups.


RESULTS
Administration of the LAB-fermented milk to SAMP1/Yit strain mice reduced histological injury score, compared with those in saline-treated or unfermented milk-treated SAMP1/Yit strain mice. Ileal tissue weight and myeloperoxidase activity also reduced by treatment of LAB-fermented milk. Moreover, the tissue contents of immunoglobulins such as IgG1 and IgG2a were lower in the inflammatory regions in the SAMP1/Yit strain group fed LAB-fermented milk than that fed saline and unfermented milk. Cytokine-specific ELISA assays indicated the production of T-helper 1 cytokines such as interferon-gamma and tumor necrosis factor-alpha in the culture supernatants of MLN cells in the SAMP1/Yit strain group fed LAB-fermented milk was lower than those fed saline and unfermented milk. On the contrary, the production of interleukin-10 in MLN cells increased by prevention with LAB-fermented milk.


CONCLUSIONS
LAB-fermented milk is beneficial for the treatment of murine IBD and this effect may be modulated through stabilization of the mucosal immunity by LAB.
Matsumoto
S
S
Yakult Central Institute for Microbiological Research, Kunitachi, Tokyo, Japan. satoshi-matumoto@yakult.co.jp
Watanabe
N
N
Imaoka
A
A
Okabe
Y
Y
D000375:Aging / Q000378:metabolism*; D000818:Animals; D001644:Bifidobacterium / Q000378:metabolism*; D002432:Cecum / Q000378:metabolism / Q000382:microbiology / Q000473:pathology; D002851:Chromatography, High Pressure Liquid; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005243:Feces / Q000382:microbiology; D005285:Fermentation / Q000502:physiology*; D005434:Flow Cytometry; D007082:Ileum / Q000378:metabolism / Q000382:microbiology / Q000473:pathology; D007136:Immunoglobulins / Q000032:analysis; D015212:Inflammatory Bowel Diseases / Q000378:metabolism* / Q000473:pathology / Q000517:prevention & control*; D007779:Lactobacillus acidophilus / Q000378:metabolism*; D008297:Male; D051379:Mice; D008892:Milk / Q000378:metabolism*; D012720:Severity of Illness Index
D007136:Immunoglobulins